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Background: Nemaline myopathy (NM) is a rare congenital myopathy characterized by muscle weakness,
hypotonia and the presence in muscle fibers of inclusions known as nemaline bodies and a wide spectrum of
clinical phenotypes, ranging from severe forms with neonatal onset to asymptomatic forms. The adult-onset form is
heterogeneous in terms of clinical presentation and disease progression. Cardiac involvement occurs in the minority
of cases and little is known about medical management in this subgroup of NM patients. We report a rare case of
heart failure (HF) in a patient with adult-onset NM in whom ivabradine proved to be able to dramatically improve
the clinical picture.
Case presentation: We report a case of a 37-year-old man with adult-onset NM, presenting with weakness and
hypotonia of the proximal limb muscles and shoulder girdle, severely limiting daily activities. He developed progressive
HF over a period of 6 months while attending a rehabilitation program, with reduced left ventricular ejection fraction
(LVEF = 20%), manifested by dyspnea and signs of systemic congestion. The patient was started HF therapy
with enalapril, carvedilol, spironolactone and loop diuretics. Target HF doses of these drugs (including carvedilol)
were not reached because of symptomatic hypotension causing a high resting heart rate (HR) ≥70 beats per minute
(bpm). Further deterioration of the clinical picture occurred with several life-threatening arrhythmic episodes requiring
external defibrillation. An implantable cardioverter defibrillator (ICD) was then implanted. Persistent high resting HR was
successfully treated with ivabradine with HR lowering from 90 bpm to 55 bpm at 1 month follow up, LVEF rising to
50% at 3 month follow up and to 54% at 2,5 year follow up. To date no more hospitalizations for heart failure occurred.
A single hospitalization due to aspiration pneumonia required insertion of a tracheostomy tube to protect airways from
further aspiration. At present, the patient is attending a regular rehabilitation program with net improvement in
neuromotor control and less limitations in daily activities.
Conclusions: HF is a rare feature of NM, but it can negatively influence prognosis. Conventional HF therapy
and/or heart transplant are the only reasonable strategy in these patients. Ivabradine is a useful, effective and
safe drug for therapy in NM patients with HF and should be considered when resting HR remains high
despite beta-blockers’ full titration or beta-blockers’ underdosing due to intolerance or side effects.
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Nemaline myopathy (NM) is an uncommon congenital
myopathy defined by the presence in muscle fibers of
inclusions known as nemaline bodies (Greek nema =
thread). In most cases muscle weakness and hypotonia
are apparent from the neonatal period or infancy but
fetal, childhood-onset and adult-onset forms are also
recognized [1]. Cardiac involvement occurs in the mi-
nority of cases, although it can cause increasing weak-
ness and physical disability [2]. No curative treatment is
currently available for NM. We report a rare case of a
patient with recently diagnosed adult-onset NM who de-
veloped progressive heart failure (HF) with reduced left
ventricular ejection fraction (LVEF) in which optimal ti-
tration of medical therapy was hampered by symptom-
atic hypotension. The adjunction of ivabradine therapy
had a decisive effect on the clinical course.
Case presentation
The patient is a 37 year-old man. His medical history
was characterized by surgery for frequent shoulder dislo-
cations at the age of 24, a traumatic injury with rupture
of anterior cruciate ligament in his left knee and chicken
pox at the age of 30. He is a cigarette smoker and has fa-
milial history of arterial hypertension and dyslipidemia.
In 2010 he started complaining of weakness in his upper
limbs and shoulder girdles (Figure 1) and an abnormalFigure 1 Hypotonia of proximal upper extremities and shoulder girdlposture with cervical hyperlordosis. In a few months he
developed progressive hypostenia at upper extremities
with involvement of lower extremities and marked in-
ability to perform daily activities (like dressing, driving,
climbing stairs). On September 2011 he was admitted to
hospital for medical investigations.
At admission, resting heart rate (HR) and blood pres-
sure were 92 beats per minute (bpm) and 100/70 mmHg,
respectively. His body surface area (BSA) was 1.64 mq.
Thoracic and heart auscultation of the heart were un-
remarkable and no signs of pulmonary or systemic con-
gestion were detected. Neurologic findings included severe
weakness and hypotonia of upper extremities, mild weak-
ness of lower extremities with slight reduction of deep ten-
don reflexes, mild weakness of the neck extensor muscles,
inability to reach Mingazzini position (I and II) without
help and waddling gait. No facial weakness nor ophthalmo-
plegia were detected.
Electromyography highlighted bilateral myogenic suf-
fering of the shoulder girdle with signs of secondary re-
organizations of motor units. Muscle biopsy of biceps
brachii showed marked variation in muscle fiber size,
atrophic type I fiber predominance and marked disarray
of contractile proteins and Z-disks; multiple cytoplasmic
nemaline rods were visible in atrophic fibers with Gomori
trichrome staining. Electron microscopy (Figure 2) re-
vealed numerous sarcoplasmic inclusions with the typicales.
Figure 2 Gomory trichrome staining showing Nemaline Rods.
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opathy was diagnosed. No familiarity for NM was proven.
The analysis of gene mutations is still in progress.
Electrocardiography (ECG) showed sinus rhythm, with
a resting HR of 92 bpm and diffuse non-specific ST-T
wave changes. Echocardiography showed left ventricular
systolic dysfunction due to diffuse hypokinesia with a
moderate reduction of left ventricular ejection fraction
(LVEF = 42%), normal dimensions of cardiac chambers,
moderate pericardial effusion with initial systolic col-
lapse of the right atrium and no signs of pulmonary
hypertension.
Spirometry revealed the presence of a moderate re-
strictive syndrome. He also underwent a cardiopulmonary
test (VO2 max: 16.7 ml/kg/min) resulting in a moderate-
severe reduction of functional capacity.
Blood test findings were normal except for a mild in-
crease in liver function tests without organic evidence of
liver abnormality at abdomen echography and computed
tomography (CT) scan. Autoanticorpal screening, viral
hepatitis and Human Immunodeficiency Virus (HIV) ser-
ology were negative. A monoclonal gammopathy of un-
determined significance was found.
Pericardiocentesis was performed because of increasing
pericardial effusion. No signs of infection or malignancy
were noted on pericardial effusion on thoraco-abdominal
CT scan.
The patient was treated with enalapril (2.5 mg b.i.d.),
carvedilol (6.25 mg b.i.d.) and spironolactone (50 mg/die).
Target HF doses of beta-blocker wasn't reached because
of symptomatic hypotension. LVEF at discharge was 50%.
In the following months the patient started a program
of intensive rehabilitation with a mild improvement inposture and gait although a worsening dysphagia was
noted.
After an initial improvement of clinical conditions, in-
creasing signs of systemic congestion occurred [progres-
sive positive fluid balance, tender hepatomegaly, jugular
distension, bilateral perimalleolar pitting edema, pleural ef-
fusion, New York Heart Association (NYHA) Class III-IV],
together with dyspnea during speech, requiring admission
to Intensive Care Unit (ICU). At admission, ECG showed
sinus rhythm with resting HR 105 bpm; blood pressure
was 90/60 mmHg. Echocardiogram revealed worsened
biventricular systolic function [LVEF = 20%; Tricuspid
Annular Plane Systolic Excursion (TAPSE) 13 mm],
with signs of initial eccentric remodeling (End Diastolic
Volume/BSA = 99 ml/mq) and mild pericardial effusion.
Treatment with dobutamine and furosemide infusion im-
proved hemodynamics but after few days three cardio-
circulatory arrests occurred due to ventricular fibrillation
and ventricular tachycardia requiring external defibril-
lation. An implantable cardioverter defibrillator (ICD)
was then implanted for secondary prevention. Ther-
apy was added with digossin, amiodarone and furosemide
but patient's resting HR at discharge was still >70 bpm
due to the aforementioned limitation in beta-blocker
titration.
On November 2011 a new rehabilitation program was
started at our institution. Ivabradine (5 mg b.i.d.) was
initiated with successful reduction of resting HR from
90 bpm to 55 bpm at 1 month follow up, also confirmed
at sixth month follow up (Figure 3). Echocardiogram
showed amelioration of left ventricular function at
3 month follow up (LVEF = 45%) (Figure 4). At 2,5 year
follow up Echocardiogram revealed recovered biventricular
Figure 3 A. ECG at baseline: sinus rhythm, 90 bpm; B. ECG at 6 month follow-up: sinus rhythm 55 bpm.
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End Diastolic Volume = 41 ml/mq, TAPSE = 21 mm).
The patient is now able to carry on the rehabilitation
program, achieving net improvement in neuromotor con-
trol of the limbs and trunk and less limitations in daily
activities. No more hospitalizations for HF occurred sinceFigure 4 Echocardiogram showing LVEF (45%) at 1 month follow upoptimization of medical therapy with ivabradine was
started with reduction of HR. However a single
hospitalization occurred for aspiration pneumonia; be-
cause of persistent dysphagia, a tracheostomy tube was
inserted to protect airways from further aspiration. At
clinical follow up ivabradine was well tolerated, theafter ivabradine introduction.
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The patient is regularly doing chest physiotherapy.
Discussion
NM is a rare congenital myopathy characterized by muscle
weakness, hypotonia and the presence in muscle fibers of
inclusions known as nemaline bodies and a wide spectrum
of phenotypes. NM is classified according to age of onset
and severity of motor and respiratory involvement and in-
cludes the severe neonatal form, Amish NM, intermediate
form, typical form, childhood-onset and adult-onset form
[1]. In patients with adult-onset form of NM symptoms
often develop between age 20 and 50 years without preced-
ing symptoms or familial history [2]. No curative treatment
is currently available for NM. A small number of affected
patients have a monoclonal gammopathy in association
with their myopathy which may be a marker of poor prog-
nosis in individuals with adult-onset NM [3-5]. Cardiac in-
volvement is uncommon and manifests as hyperthropic
cardiomyopathy or, more frequently, as dilated cardiomy-
opathy with HF [6-9]. Notably, cardiac and respiratory in-
volvement implies a worse prognosis [2]. Conventional HF
therapy and/or heart transplant are, at the moment, the
only reasonable strategies in these patients.
We reported a case of adult-onset NM with progressive
HF. The clinical and pathological findings of our patient
were similar to those of previously described cases of adult-
onset nemaline myopathy [2-4,10-12] including proximal
muscle weakness, dysphagia, lack of familiarity involve-
ment or preceding symptoms and monoclonal gammopa-
thy. Symptomatic hypotension significantly limited optimal
titration of Angiotensin Converting Enzyme (ACE)-
inhibitors and mostly of beta-blockers with a consequent
persistent elevated resting HR.
High resting HR has been shown to correlate with
clinical outcome both in the general population and in
patients with cardiovascular disease [13,14]. Resting
HR may also have an independent prognostic value in
chronic HF and is a potentially modifiable cardiovascular
risk factor [15-17]. Several HF clinical trials showed that
reaching recommended target doses of beta-blockers re-
sults in better outcomes [18-21]. Moreover, recent meta-
analysis of beta-blockers trials in HF found that the mag-
nitude of HR reduction was more important than the
achievement of target dose in predicting improved out-
come [22,23]. Notably, beta-blockers are generally well
tolerated but side effects may occur which may require
drug withdrawal or a dose reduction, as in the case of our
patient [24].
High resting HR is currently considered a marker of de-
compensated HF and its persistence despite optimal beta-
blocker titration or following beta-blocker undertitration
(due to drug intolerance or side effects occurrence) consti-
tutes an indication for treatment with ivabradine.Ivabradine is a purely HR-lowering drug that acts by
inhibiting the diastolic If current in the sinus node. It
has proven to be effective and safe in improving clinical
outcome in HF (mainly HF hospitalization and NYHA
class) [25,26]. It is noteworthy that ivabradine has no ac-
tion on other channels in the heart or vascular system,
then it does not affect myocardial contractility or atrio-
ventricular conduction. A previous report by Taglia et al.
[27] reported a similar case of adult-onset NM with car-
diac involvement in whom ivabradine ameliorated the
clinical picture. In this report beta-blocker was substituted
with ivabradine after about 12 years of follow up, likely be-
cause of the severe respiratory insufficiency. Conversely
instable hemodynamics and hypotension were predomin-
ant in our patient and requiring early therapeutic counter-
measures to obtain a better hemodynamic compensation.
Ivabradine introduction coincided with a significant
clinical improvement, achieving resting HR <70 bpm
and contractility improvement with increased LVEF. Also,
no more hospitalizations for HF occurred since ivabradine
was started and the patient was able to carry on the re-
habilitation program with net improvement of his
clinical conditions.
Conclusions
HF is a rare feature of NM, but it can negatively influence
prognosis. Conventional HF therapy and/or heart trans-
plant are the only reasonable strategy in these patients.
Ivabradine is a useful, effective and safe drug for therapy
in NM patients with HF and should be considered when
HR remains high even though ACE-inhibitors and beta-
blockers are given or are underdosed due to intolerance
or side effects.
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